- |||||||||| namodenoson (CF102) - Can / Fite
Journal: A Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity. (Pubmed Central) - Feb 27, 2022
In particular, the N-(2,2-diphenylethyl)-2-phenylethynylAdo (12: GI = 14 µM, TGI = 29 µM, and LC = 59 µM) showed the highest activity proving to be a potential antitumor agent. The cytostatic effect of both AAR agonist (Cl-IB-MECA) and antagonists (12 and other newly synthesized compounds) confirm previous observations according to which, in addition to the involvement of AARs, other cellular mechanisms are responsible for the anticancer effects of these ligands.
- |||||||||| piclidenoson (CF101) - Can / Fite, Cipher, China Medical System
Enrollment closed, Trial primary completion date: CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - Feb 24, 2022
P3, N=528, Active, not recruiting,
The functionality of the heteromer in primary microglia from APP mice was more similar to that found in resting microglia from control mice. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Apr 2022
- |||||||||| piclidenoson (CF101) - Can / Fite, Cipher, China Medical System
Enrollment closed, Enrollment change: Piclidenoson for Treatment of COVID-19 (clinicaltrials.gov) - Dec 30, 2021
P2, N=6, Active, not recruiting,
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=40 --> 6
- |||||||||| namodenoson (CF102) - Can / Fite
Adenosine Signaling Perturbs Erythropoiesis and Promotes Myeloid Differentiation (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_3591;
Both BAY60-6583 and CI-IB-MECA increased apoptosis and decreased erythroblast maturation and enucleation, while only Cl-IB-MECA led to the upregulation of CD33 and CD11a myeloid markers and promoted the differentiation of a GPA neg myeloid subpopulation...While the activation of A 2B hampers optimal erythropoiesis without impacting the myeloid differentiation. As both ineffective erythropoiesis and increased leucocyte counts are reported in SCD, and given the detrimental role of high adenosine levels in its pathophysiology, further studies are ongoing to address the impact of adenosine signaling on hematopoiesis in this disease.
- |||||||||| namodenoson (CF102) - Can / Fite
Journal: A Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma. (Pubmed Central) - Oct 22, 2021
The AAR agonist Cl-IB-MECA and the P2X7 receptor antagonist AZ10606120, as a single compound or in combination, were investigated in vitro for their anti-tumor activities...These data cumulatively suggest the absence of a synergistic effect in combined targeting of A adenosine and P2X7 receptors of MPM cell lines. This study may stimulate further investigations aimed at determining new combinations of antitumor compounds and more effective therapeutic strategies against MPM.
- |||||||||| namodenoson (CF102) - Can / Fite, China Medical System
Review, Journal: Uncovering the Mechanisms of Adenosine Receptor-Mediated Pain Control: Focus on the A Receptor Subtype. (Pubmed Central) - Sep 11, 2021
Recent evidence showed that the prototypical AAR agonist Cl-IB-MECA and the new, highly selective, AAR agonist MRS5980 inhibit neuronal (N-type) voltage-dependent Ca currents in dorsal root ganglia, a known pain-related mechanism...The aim of this review is to summarize up-to-date information on AAR in the context of pain, including cellular and molecular mechanisms underlying this effect. Based on their safety profile shown in clinical trials for other pathologies, AAR agonists are proposed as novel, promising non-narcotic agents for pain control.
- |||||||||| namodenoson (CF102) - Can / Fite, China Medical System
Preclinical, Journal: Design and in vivo activity of A adenosine receptor agonist prodrugs. (Pubmed Central) - Aug 20, 2021
Prodrugs (MRS7422, MRS7476) of highly selective A adenosine receptor (AR) agonists Cl-IB-MECA and MRS5698, respectively, were synthesized by succinylation of the 2' and 3' hydroxyl groups, and the parent, active drug was shown to be readily liberated upon incubation with liver esterases...Adora3 expression determined by qPCR in primary mouse liver was associated with the stellate cells, and its mouse full body AAR knockout worsened liver markers of inflammation and steatosis. Thus, we have introduced a reversible prodrug strategy that enables water solubility and in vivo activity of masked AAR agonists in models of two disease conditions.
- |||||||||| namodenoson (CF102) - Can / Fite
Trial initiation date: Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Jul 1, 2021
P2b, N=114, Not yet recruiting,
Highly promising biologicals and small oral molecules are the leading edge of the systemic treatment of psoriasis. Initiation date: Mar 2021 --> Aug 2021
- |||||||||| CF602 - Can / Fite, namodenoson (CF102) - Can / Fite, China Medical System, piclidenoson (CF101) - Can / Fite, China Medical System
[VIRTUAL] Can-Fite BioPharma () - May 31, 2021 - Abstract #BIO2021BIO_282;
Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH)...CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date.
- |||||||||| piclidenoson (CF101) - Can / Fite, Cipher, China Medical System
Trial completion date, Trial primary completion date: Piclidenoson for Treatment of COVID-19 (clinicaltrials.gov) - Mar 23, 2021
P2, N=40, Recruiting,
A3AR agonists are effective in relieving visceral hypersensitivity induced by DNBS, suggesting a potential therapeutic role against abdominal pain. Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
- |||||||||| namodenoson (CF102) - Can / Fite, China Medical System
Journal: Activation of adenosine A receptor protects retinal ganglion cells from degeneration induced by ocular hypertension. (Pubmed Central) - Mar 13, 2021
Moreover, the treatment of OHT eyes with the AR agonist promoted the survival of RGCs, attenuated the impairment in retrograde axonal transport, and improved the structure of the optic nerve. Taking into consideration the beneficial effects afforded by 2-Cl-IB-MECA, we can envisage that AR activation can be considered a good therapeutic strategy to protect RGCs from glaucomatous damage.
- |||||||||| namodenoson (CF102) - Can / Fite
Trial completion date, Metastases: Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Feb 25, 2021
P2, N=78, Active, not recruiting,
Taking into consideration the beneficial effects afforded by 2-Cl-IB-MECA, we can envisage that AR activation can be considered a good therapeutic strategy to protect RGCs from glaucomatous damage. Trial completion date: Dec 2020 --> Dec 2021
- |||||||||| namodenoson (CF102) - Can / Fite, China Medical System
Journal: Activation of Adenosine A Receptor Inhibits Microglia Reactivity Elicited by Elevated Pressure. (Pubmed Central) - Feb 24, 2021
In retinal microglia, proliferation and phagocytosis elicited by EHP were also decreased by AR activation. This work demonstrates that 2-Cl-IB-MECA, the selective agonist of AR, is able to hinder microglia reactivity, suggesting that AR agonists could afford protection against glaucomatous degeneration through the control of neuroinflammation.
- |||||||||| Xeljanz (tofacitinib) / Pfizer, Marche Polytechnic University
Journal: Emerging systemic drugs in the treatment of plaque psoriasis. (Pubmed Central) - Feb 4, 2021
There seems to be limited room for development of novel biologics, as the existing ones are extraordinarily safe, effective, and convenient with few injections. Patients would prefer a safe, effective oral treatment; however, JAK inhibitors seem unlikely to fill this role completely.
- |||||||||| piclidenoson (CF101) - Can / Fite, Cipher, China Medical System
Enrollment open: Piclidenoson for Treatment of COVID-19 (clinicaltrials.gov) - Jan 27, 2021
P2, N=40, Recruiting,
Patients would prefer a safe, effective oral treatment; however, JAK inhibitors seem unlikely to fill this role completely. Not yet recruiting --> Recruiting
- |||||||||| piclidenoson (CF101) - Can / Fite
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 19, 2020
P3, N=244, Terminated,
In conclusion, namodenoson demonstrated a favorable safety profile and a preliminary efficacy signal in HCC CPB. N=525 --> 244 | Trial completion date: Sep 2021 --> Nov 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2021 --> Nov 2020; Interim analysis results
- |||||||||| piclidenoson (CF101) - Can / Fite, Cipher, China Medical System
Enrollment open, Trial completion date, Trial primary completion date: CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - Dec 17, 2020
P3, N=525, Recruiting,
N=525 --> 244 | Trial completion date: Sep 2021 --> Nov 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2021 --> Nov 2020; Interim analysis results Active, not recruiting --> Recruiting | Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Feb 2021 --> Dec 2021
- |||||||||| piclidenoson (CF101) - Can / Fite, Cipher, China Medical System
Trial initiation date: Piclidenoson for Treatment of COVID-19 (clinicaltrials.gov) - Dec 3, 2020
P2, N=40, Not yet recruiting,
Active, not recruiting --> Recruiting | Trial completion date: Dec 2021 --> Mar 2022 | Trial primary completion date: Feb 2021 --> Dec 2021 Initiation date: Oct 2020 --> Jan 2021
- |||||||||| piclidenoson (CF101) - Can / Fite
Trial completion date, Trial primary completion date: CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis (clinicaltrials.gov) - Aug 8, 2020
P3, N=525, Active, not recruiting,
A3AR activation may play a role in the pathogenesis of UC. Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- |||||||||| piclidenoson (CF101) - Can / Fite, Cipher, China Medical System
Trial completion date, Trial initiation date, Trial primary completion date: Piclidenoson for Treatment of COVID-19 (clinicaltrials.gov) - Jul 7, 2020
P2, N=40, Not yet recruiting,
Trial completion date: Dec 2019 --> Dec 2020 Trial completion date: Jul 2020 --> Jul 2021 | Initiation date: Apr 2020 --> Sep 2020 | Trial primary completion date: Jun 2020 --> Mar 2021
- |||||||||| piclidenoson (CF101) - Can / Fite, Cipher, China Medical System
New P2 trial: Piclidenoson for Treatment of COVID-19 (clinicaltrials.gov) - Apr 2, 2020
P2, N=40, Not yet recruiting,
- |||||||||| piclidenoson (CF101) - Can / Fite, Cipher, China Medical System
Enrollment closed, Trial completion date, Trial primary completion date: CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - Mar 31, 2020
P3, N=407, Active, not recruiting,
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Feb 2020 --> Feb 2021
|
